Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges [Yahoo! Finance]
Talphera, Inc. (TLPH)
Company Research
Source: Yahoo! Finance
Talphera Inc ( NASDAQ:TLPH ) has successfully onboarded five active clinical trial sites with plans to expand to seven by the end of the year, indicating progress in their ongoing registrational trial. The company is implementing innovative strategies to improve patient enrollment, such as automated text notifications and report generations from electronic medical records. Talphera Inc ( NASDAQ:TLPH ) has a clear regulatory path with a product candidate that has breakthrough designation from the FDA, which provides quick review and response times. The company has a strong track record of safety and efficacy for their product, Nafamostat, which has been used as an anticoagulant for CRRT for 30 years in Japan and South Korea. Talphera Inc ( NASDAQ:TLPH ) has expressed confidence in the commercial potential of Nafamostat, citing a clear unmet need for an alternative anticoagulant in CRRT. The initial activation and enrollment rates at clinical trial sites have not met Talphera
Show less
Read more
Impact Snapshot
Event Time:
TLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLPH alerts
High impacting Talphera, Inc. news events
Weekly update
A roundup of the hottest topics
TLPH
News
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors [Yahoo! Finance]Yahoo! Finance
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR Newswire
- Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Talphera, Inc. (NASDAQ: TLPH) was upgraded by analysts at Maxim Group to a "strong-buy" rating.MarketBeat
- Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024PR Newswire
TLPH
Earnings
- 11/13/24 - Beat
TLPH
Analyst Actions
- 11/12/24 - Maxim Group
TLPH
Sec Filings
- 12/11/24 - Form 8-K
- 12/6/24 - Form 4
- 12/2/24 - Form 4
- TLPH's page on the SEC website